Form 4: Atara Biotherapeutics Director Maria Grazia Roncarolo Acquires 150,000 Shares of Common Stock

Director Maria Grazia Roncarolo acquired 150,000 shares of Atara Biotherapeutics common stock on March 31, 2024, as reported in a Form 4 filing.

Summary

• Maria Grazia Roncarolo, a director of Atara Biotherapeutics, acquired 150,000 shares of common stock on March 31, 2024.
• The acquisition was made at a price of $0 per share.
• Following the transaction, Roncarolo directly owns 238,500 shares of Atara Biotherapeutics common stock.
• The filing also indicates that Roncarolo was granted restricted stock units that will vest on the date of the Issuer's annual meeting of stockholders for the calendar year 2025, subject to continuous service.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard insider transaction report. The director's stock purchase could be interpreted as a positive signal, but it's not overwhelmingly significant.

Positives

• A director's acquisition of company stock can be seen as a positive signal, indicating confidence in the company's future prospects.

Future Outlook

The vesting of restricted stock units in 2025 is contingent upon the reporting person's continuous service.

Industry Context

Form 4 filings are a routine part of regulatory compliance for corporate insiders and provide transparency into their transactions in company stock.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment.

Key Dates